Health

Health

Public health, medicine, mental health, outbreaks, and healthcare systems.

health

FDA OKs Pfizer’s TUKYSA for Front‑line Maintenance in HER2‑Positive Metastatic Breast Cancer

FDA expands Pfizer's TUKYSA for front‑line maintenance in unresectable/metastatic HER2‑positive breast cancer; PFS improved 8.6 months, liver risks noted.

$PFE, #her2, #breastcancer, #pfizer, #fda

health

Federal Medicaid Match Ends for Many Lawfully Present Immigrants, Forcing States to Decide

New federal rule ends Medicaid/CHIP matching funds for many lawfully present immigrants starting Oct. 1, 2026, forcing states to cut coverage or pay locally.

#medicaid, #immigration, #healthcare, #cms

health

Garetosmab (Pasatru) sharply reduces new bone lesions in adults with FOP, phase 3 Lancet trial shows; FDA approved Aug. 19, 2026

Phase 3 Lancet trial shows garetosmab cuts new heterotopic bone lesions by ~90% in adults with FOP; FDA approved Pasatru Aug. 19, 2026.

#fop, #garetosmab, #raredisease, #fda

health

Single IV CRISPR Dose Produces ~50% LDL and Triglyceride Reductions at One Year in Early Trial

A single IV dose of CRISPR Therapeutics’ CTX310 produced about 50% average reductions in LDL cholesterol and triglycerides at one year in a small Phase 1a trial.

$CRSP, #crispr, #lipids, #geneediting, #angptl3

health

NHS launches pilot of rapid genomic test to cut brain tumour diagnosis from weeks to days

NHS England is piloting a rapid genomic test for brain tumours in five specialist centres, aiming to shorten diagnosis from weeks to days.

#nhs, #genomics, #brain-tumour, #diagnostics, #oncology

health

NHS-Galleri Trial Misses Primary Endpoint; Secondary Analysis Shows Fewer Stage IV Cancers

A large randomized NHS trial of Grail’s Galleri multi-cancer blood test missed its primary endpoint, though secondary analysis found fewer Stage IV cancers.

#cancer, #screening, #galleri, #clinicaltrials

health

England dashboard: 1.4 million waiting for mental health care as NHS outlines £21.4bn 2026/27 plans

NHS England’s new quarterly dashboard shows 1.415m people waiting for mental-health care in July and planned mental-health spending of £21.376bn for 2026/27.

#mentalhealth, #nhs, #england, #healthpolicy

health

Lancet urges compassionate care as central to controlling DRC’s Bundibugyo Ebola outbreak

A Lancet commentary argues that accessible, high-quality supportive care is essential to controlling the DRC’s growing Bundibugyo Ebola outbreak.

#ebola, #drc, #publichealth, #lancet

health

Durvalumab Plus FLOT Boosts Survival in Resectable Gastric and GEJ Cancer, MATTERHORN Shows

Phase 3 MATTERHORN shows AstraZeneca’s durvalumab added to perioperative FLOT improves overall and event‑free survival in resectable gastric/GEJ cancer.

$AZN, #oncology, #immunotherapy, #durvalumab, #gastric-cancer, #astrazeneca

health

Gene-edited pig kidney supported a human for 271 days and didn’t block later transplant, case report finds

A Lancet case report shows a gene-edited pig kidney kept a patient off dialysis for 271 days and didn’t impede a later human transplant.

#xenotransplantation, #kidneytransplant, #egenesis, #organtransplant

health

FDA Approves Zanvastro, First Therapy for Alexander Disease

FDA approves Zanvastro (zilganersen), the first approved therapy for Alexander disease, for patients from infancy through adulthood. Ionis received approval.

$IONS, #health, #fda, #alexanderdisease, #ionis

health

Sham-controlled trial finds pulmonary vein isolation no better than sham for atrial fibrillation quality of life at six months

A multicentre sham-controlled trial in Europe published in The Lancet found PVI didn’t improve AF-related quality of life versus sham at six months.

#atrialfibrillation, #catheterablation, #cardiology, #clinicaltrials

health

Phase 1 study: single dose of Kylo-11 sharply lowers Lp(a) for up to 48 weeks

A phase 1 trial in The Lancet found one dose of experimental siRNA Kylo-11 was well tolerated and cut Lp(a) by up to ~98% for months.

#lpa, #cardiology, #drugdevelopment, #sirna

health

FDA Approves Rasonque (daraxonrasib), First Targeted Therapy for Most Common Form of Metastatic Pancreatic Cancer

FDA cleared Rasonque for adults with previously treated metastatic pancreatic adenocarcinoma after a Phase 3 trial showed a significant overall survival benefit.

$RVMD, #health, #pancreaticcancer, #oncology, #drugapproval

health

FDA Clears Abbott’s Libre Duo 10 Day, First U.S. Wearable to Continuously Monitor Ketones and Glucose

FDA authorizes Abbott’s Libre Duo 10 Day, the first U.S. wearable to continuously monitor ketones and glucose for ages 2 and up.

#diabetes, #fda, #medicaldevices, #abbott